PW Medtech Group (FRA:PWE) Moat Score: 0/10 (As of Jul. 07, 2026)


FRA:PWE PW Medtech Group Ltd FRA:PWE
84 GF Score
Price €0.11
GF Value €0.13
! 6 Warning Signs
View Full Analysis

What is PW Medtech Group Moat Score?

PW Medtech Group has the Moat Score of 0, which implies that the company might have No Moat - No discernible moat.

PW Medtech Group has

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes PW Medtech Group might have No Moat - No discernible moat.

PW Medtech Group  (FRA:PWE) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

PW Medtech Group Moat Score Related Terms

FRA:PWE
84GF Score
PW Medtech Group Ltd FRA:PWE
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is PW Medtech Group (FRA:PWE) Overvalued in 2026?

Based on GuruFocus' analysis, PW Medtech Group stock appears to be undervalued. The current stock price of €0.11 is trading 18.5% below its estimated GF Value™ of €0.13.

Key valuation signals for FRA:PWE:

  • Moat Score: 0
  • GF Value™: €0.13 vs. price of €0.11 (18.5% below fair value)
  • GF Score™: 84/100 with 6 warning signs

No single metric tells the full story. See the FRA:PWE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

PW Medtech Group Business Description

Other Exchanges 01358:Hong Kong
Address No. 23 Panlong West Road, Building 1, Pinggu District, Beijing, CHN, 101204
PW Medtech Group Ltd is a medical device company focused on China's medical device industry. The Group operates in infusion sets, blood purification products, and regenerative medical biomaterials. Its products include non-PVC-based infusion sets, precision filter infusion sets, light-resistant infusion sets, intravenous cannula products, insulin needles and pens, high flux and low flux hemodialyzers, hemodiafilters, hemoperfutors, and dialysis machines. Its segments are Infusion Set Business, Blood Purification Business, which represents the R&D, manufacturing, and sales of hemodialysis and blood purification medical devices, and Regenerative Medical Biomaterials Business, which generates maximum revenue. Geographically, it operates in China, North America, India and Others.
84GF Score

Get the complete analysis for FRA:PWE

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.11
Price
€0.13
GF Value